Galena Biopharma (GALE) Announces Common Offering
Tweet
Share
E-mailGet Alerts GALE Hot Sheet
Join SI Premium – FREE
Galena Biopharma (Nasdaq: GALE), intends to offer shares of its common stock in an underwritten public offering. Roth Capital Partners, LLC is acting as the sole book-running manager for the offering.
The company intends to use the net proceeds of the offering for working capital and other general corporate purposes, including the Phase 3 NeuVax (E75) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial, Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a planned Phase 2 trial of NeuVax in combination with Herceptin (trastuzumab; Genentech/Roche).
The company intends to use the net proceeds of the offering for working capital and other general corporate purposes, including the Phase 3 NeuVax (E75) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial, Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a planned Phase 2 trial of NeuVax in combination with Herceptin (trastuzumab; Genentech/Roche).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ESS Tech closes $3.2M stock offering at $0.50 per share
- Thunder Mountain Gold closes $5.7M private placement
- Aptevo Therapeutics files prospectus for resale of 6.4M shares
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
